Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies

Blood

Volumn 99, Issue 9, 2002, Pages 3272-3279

  Elisseeva, Olga A ^{a,b,c,d,e,f,g,h}   Oka, Yoshihiro ^{a,b,c,d,e,f,g,h}   Tsuboi, Akihiro ^{a,b,c,d,e,f,g,h}   Ogata, Kiyoyuki ^{a,b,c,d,e,f,g,h}   Wu, Fei ^{a,b,c,d,e,f,g,h}   Kim, Eui Ho ^{a,b,c,d,e,f,g,h}   Soma, Toshihiro ^{a,b,c,d,e,f,g,h}   Tamaki, Hiroya ^{a,b,c,d,e,f,g,h}   Kawakami, Manabu ^{a,b,c,d,e,f,g,h}   Oji, Yusuke ^{a,b,c,d,e,f,g,h}   Hosen, Naoki ^{a,b,c,d,e,f,g,h}   Kubota, Takeshi ^{a,b,c,d,e,f,g,h}   Nakagawa, Masashi ^{a,b,c,d,e,f,g,h}   Yamagami, Tamotsu ^{a,b,c,d,e,f,g,h}   Hiraoka, Akira ^{a,b,c,d,e,f,g,h}   Tsukaguchi, Machiko ^{a,b,c,d,e,f,g,h}   Udaka, Keiko ^{a,b,c,d,e,f,g,h}   Ogawa, Hiroyasu ^{a,b,c,d,e,f,g,h}   Kishimoto, Tadamitsu ^{a,b,c,d,e,f,g,h}   Nomura, Taisei ^{a,b,c,d,e,f,g,h}   Sugiyama, Haruo ^{a,b,c,d,e,f,g,h}   more..

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^d Nippon Life Saiseikai Foundation   (Japan)

^e CENTER FOR ADULT DISEASES   (Japan)

^f SAKAI MUNICIPAL HOSPITAL   (Japan)

^g KYOTO UNIVERSITY   (Japan)

^h OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROTEIN WT1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIBODY DETECTION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DOT HYBRIDIZATION; GENE EXPRESSION; GENE FUNCTION; HELPER CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGLOBULIN GENE; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NEPHROBLASTOMA; ONCOGENE; PRIORITY JOURNAL; REFRACTORY ANEMIA;

EID: 0036566202     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3272     Document Type: Article

References (72)

1. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
2. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping
3. The role of WT1 in Wilms tumorigenesis
4. The WT1 Wilms tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor
5. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant
6. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumour associated with high levels of expression of a truncated transcript
7. A clinical overview of WT1 gene mutations
8. The Wilms' tumor 1 gene: Oncogene or tumor suppressor gene
9. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1
10. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus
11. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
12. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1 R promoter activity by the WT1 Wilms tumor gene product
13. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis
14. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1
15. Repression of the c-myb gene by WT1 protein in T and B cell lines
16. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1
17. Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1
18. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1
19. Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition
20. The Wilms' tumor suppressor gene (wtl) product regulates Dax-1 gene expression during gonadal differentiation
21. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene
22. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development
23. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma
24. Multiple roles for the Wilms' tumor suppressor, WT1
25. YAC complementation shows a requirement for WT1 in the development of epicardium, adrenal gland and throughout nephrogenesis
26. Expression of the Wilms' tumor gene (WT1) in human leukemias
27. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells
28. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
29. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells
30. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
31. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia
32. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors
33. E Molecular mechanisms possibly affecting WT1 function in human ovarian tumors
34. Wilms' tumor suppressor gene expression in rat and human mesothelioma
35. Expression of the wtl Wilms' tumor gene by normal and malignant human melanocytes
36. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor
37. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma
38. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression
39. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer
40. Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma
41. Expression of the Witms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth
42. WT1 gene expression in human testicular germ-cell tumors
43. Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens
44. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis
45. AWT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines
46. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells
47. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)
48. WT1 contributes to leukemogenesis: Expression patterns in 7,12-dimethylbenzanthracene (DMBA)-induced leukemia
49. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
50. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1
51. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide
52. Cancer immunotherapy targeting Wilms' tumor gene WT1 product
53. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
54. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination
55. Tumor antigens
56. T cell defined tumor antigens
57. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes
58. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine
59. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
60. Monitoring CDB T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
61. T cell tolerance by clonal elimination in the thymus
62. Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity
63. T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I-E
64. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction
65. Homing of naive, memory and effector lymphocytes
66. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
67. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response
68. Autoimmunity caused by ignorant CDB+ T cells is transient and depends on avidity
69. p53 antibodies in the sera of patients with various types of cancer: A review
70. Serum p53 antibodies as early markers of lung cancer
71. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer
72. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer